Stock Scorecard
Stock Summary for EyePoint Pharmaceuticals Inc (EYPT) - $18.18 as of 4/19/2024 7:28:40 AM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EYPT
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EYPT
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EYPT
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for EYPT
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for EYPT
Financial Details for EYPT
Company Overview |
|
---|---|
Ticker | EYPT |
Company Name | EyePoint Pharmaceuticals Inc |
Country | USA |
Description | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | LABORATORY ANALYTICAL INSTRUMENTS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/1/2024 |
Stock Price History |
|
Last Day Price | 18.18 |
Last Day Price Updated | 4/19/2024 7:28:40 AM EST |
Last Day Volume | 4,141,681 |
Average Daily Volume | 867,467 |
52-Week High | 30.99 |
52-Week Low | 5.32 |
Last Price to 52 Week Low | 241.73% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 28.90 |
Sector PE | 61.34 |
5-Year Average PE | -4.38 |
Free Cash Flow Ratio | 2.74 |
Industry Free Cash Flow Ratio | 100.20 |
Sector Free Cash Flow Ratio | 30.17 |
Current Ratio Most Recent Quarter | 5.45 |
Total Cash Per Share | 6.64 |
Book Value Per Share Most Recent Quarter | 5.43 |
Price to Book Ratio | 4.20 |
Industry Price to Book Ratio | 801.96 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 24.31 |
Industry Price to Sales Ratio Twelve Trailing Months | 4.44 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
Total Shares Outstanding | 49,830,800 |
Market Capitalization | 905,923,944 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.26% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 30.77% |
Reported EPS 12 Trailing Months | -1.82 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -1.83 |
Net Income Twelve Trailing Months | -70,795,000 |
Net Income Past Year | -70,795,000 |
Net Income Prior Year | -102,254,000 |
Quarterly Revenue Growth YOY | 33.20% |
5-Year Revenue Growth | 37.20% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 331,000,000 |
Total Cash Past Year | 331,000,000 |
Total Cash Prior Year | 142,500,000 |
Net Cash Position Most Recent Quarter | 301,000,000 |
Net Cash Position Past Year | 301,000,000 |
Long Term Debt Past Year | 30,000,000 |
Long Term Debt Prior Year | 30,000,000 |
Total Debt Most Recent Quarter | 30,000,000 |
Equity to Debt Ratio Past Year | 0.90 |
Equity to Debt Ratio Most Recent Quarter | 0.90 |
Total Stockholder Equity Past Year | 266,323,000 |
Total Stockholder Equity Prior Year | 57,262,000 |
Total Stockholder Equity Most Recent Quarter | 266,323,000 |
Options |
|
Put/Call Ratio | 0.09 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.59 |
MACD Signal | -0.83 |
20-Day Bollinger Lower Band | 16.58 |
20-Day Bollinger Middle Band | 23.29 |
20-Day Bollinger Upper Band | 29.99 |
Beta | 1.68 |
RSI | 44.21 |
50-Day SMA | 14.54 |
200-Day SMA | 9.95 |
System |
|
Modified | 4/18/2024 12:11:06 AM EST |